INDIVIOR PLC SEC 10-Q Report

Indivior PLC, a global leader in addiction treatment, has released its Form 10-Q report for the second quarter of 2025. The report highlights significant improvements in both financial and operational performance, driven by increased sales of key products and effective cost management strategies.

Financial Highlights

Net Revenue: Indivior PLC reported net revenue of $302 million for the three months ended June 30, 2025, marking a 1% increase from $299 million in the same period in 2024. This growth was primarily driven by a 9% increase in SUBLOCADE sales.

Gross Profit: The company achieved a gross profit of $250 million for the three months ended June 30, 2025, up from $220 million in the same period in 2024. This improvement reflects a gross margin increase to 83% from 74%, attributed to reduced costs related to PERSERIS.

Operating Income: Indivior reported an operating income of $72 million for the three months ended June 30, 2025, compared to an operating loss of $118 million in the same period in 2024. The turnaround was primarily due to the absence of litigation settlement expenses.

Net Income: The company posted a net income of $18 million for the three months ended June 30, 2025, compared to a net loss of $97 million in the same period in 2024. This reflects improved operating performance and effective cost management.

Basic Earnings (Loss) Per Share: Basic earnings per share were $0.15 for the three months ended June 30, 2025, compared to a loss of $0.72 in the same period in 2024, indicating a significant turnaround in profitability.

Diluted Earnings (Loss) Per Share: Diluted earnings per share were $0.14 for the three months ended June 30, 2025, compared to a loss of $0.72 in the same period in 2024, highlighting improved financial performance.

Business Highlights

Revenue Segments: SUBLOCADE accounted for 69% and 68% of net revenue for the three and six months ended June 30, 2025, respectively. Other buprenorphine-based sublingual products accounted for 27% and 29% of net revenue for the same periods.

Geographical Performance: U.S. net revenue from SUBLOCADE increased by 9% and 4% in the three and six months ended June 30, 2025, respectively, reflecting volume increases and changes in rebate accruals. Rest of the World net revenue increased by 5% and 4% in the same periods, driven by newer products like SUBLOCADE / SUBUTEX Prolonged Release.

Sales Units: The U.S. market remains the largest, with SUBOXONE Film having an oral buprenorphine medically assisted treatment (BMAT) average share of 14.4% in the three months ended June 30, 2025.

New Production Launches: The company is finalizing the SUBLOCADE suite at the Raleigh Manufacturing Facility, with expected capital expenditures of $50 million to $70 million for the full year 2025.

Future Outlook: Indivior expects gross margin to continue in the low-to-mid 80 percent range for the remainder of 2025. Research and development expenses are expected to track below 2024 levels throughout 2025, focusing on Phase 2 OUD assets.

SEC Filing: INDIVIOR PLC [ INDV ] - 10-Q - Jul. 31, 2025